Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy
of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the
acetylcholinesterase (AChE) inhibitor. The effects of add-on Circadin® 2mg vs. placebo on the
decline in cognitive skills and global functioning, as well as on daytime somnolence and will
be assessed.